Prevention of diabetes macrovascular complications and heart failure

Sattar, N. (2021) Prevention of diabetes macrovascular complications and heart failure. Endocrinology and Metabolism Clinics of North America, 50(3), pp. 415-430. (doi: 10.1016/j.ecl.2021.05.004) (PMID:34399954)

Abstract

Cardiovascular (CV) mortality in diabetes has declined substantially over the last 3 decades in high-income countries from a multifactorial approach targeting glucose, cholesterol, and blood pressure, and lower smoking rates. Additional CV gains may be achieved from large-scale weight loss, which ongoing trials are testing, and from delaying diabetes in those at highest risk. Finally, recent outcome trials support a role for (1) sodium/glucose cotransporter-2 inhibitors, which lower major adverse cardiovascular events but incident heart failure more strongly, and (2) glucagon-like peptide-1 receptor agonists, which lower atherothrombotic outcomes more consistently, including stroke and peripheral arterial disease.

• Item Type: Articles
• Keywords: LDL-cholesterol, obesity, SGLT2i, countries, hypertension, ethnicity, GLP-1RA, metformin.
• Status: Published
• Refereed: Yes
• Glasgow Author(s) Enlighten ID: Sattar, Professor Naveed
• Authors: Sattar, N.
• College/School: College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health
• Journal Name: Endocrinology and Metabolism Clinics of North America
• Publisher: Elsevier
• ISSN: 0889-8529
• ISSN (Online): 1558-4410
• Published Online: 12 July 2021
• Copyright Holders: Copyright © 2021 Elsevier
• First Published: First published in Endocrinology and Metabolism Clinics of North America 50(3):415-430
• Publisher Policy: Reproduced in accordance with the copyright policy of the publisher